|
- 1-8: Acyclovir [Susceptibility]
- 10-9: Amdinocillin [Susceptibility] by Serum bactericidal titer
- 100-8: Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC)
- 1000-9: DBG Ab [Presence] in Serum or Plasma from Blood product unit
- 10000-8: R wave duration in lead AVR
- 100002-5: Specimen care is maintained
- 100003-3: Team communication is maintained throughout care
- 100004-1: Demonstrates knowledge of the expected psychosocial responses to the procedure
- 100005-8: Demonstrates knowledge of nutritional management related to the procedure
- 100006-6: Demonstrates knowledge of medication management
- 100007-4: Demonstrates knowledge of pain management
- 100008-2: Demonstrates knowledge of wound management
- 100009-0: Demonstrates knowledge of the procedure and expected results
- 10001-6: R wave duration in lead I
- 100010-8: No injury related to procedure equipment, medical supplies, or instrumentation
- 100011-6: No injury related to an electrical source
- 100012-4: Participates in decisions affecting the patient's plan of care
- 100013-2: Participates in the discharge process
- 100014-0: Psychosocial health is maintained at or improved from baseline
- 100015-7: No injury related to positioning due to care or procedure
- 100016-5: No injury related to a laser source
- 100017-3: Perioperative nursing data set outcomes panel [PNDS]
- 100018-1: Hospice care Note
- 100019-9: ALK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 10002-4: R wave duration in lead II
|
- 100020-7: GNA11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100021-5: GNAQ gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100022-3: IDH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100023-1: IDH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100024-9: SETBP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100025-6: SRSF2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100026-4: MET gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100027-2: SMAD4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100028-0: FBXW7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal
- 100029-8: Cancer related multigene analysis in Plasma cell-free DNA by Molecular genetics method
- 10003-2: R wave duration in lead III
- 100030-6: Axis I: Temporal aspects score [Mainz Pain Staging System]
- 100031-4: Axis II: Spatial aspects score [Mainz Pain Staging System]
- 100032-2: Axis III: Drug taking behavior score [Mainz Pain Staging System]
- 100033-0: Axis IV: Utilization of the health care system score [Mainz Pain Staging System]
- 100034-8: Provider of automated external defibrillator use
- 100035-5: Exam finding location of Chest
- 100036-3: Exam finding location of Lung
- 100037-1: Patient contact disposition EMS unit
- 100038-9: Patient evaluation disposition EMS unit
- 100039-7: Crew disposition for patient care EMS unit
- 10004-0: R wave duration in lead V1
- 100040-5: Patient transport disposition EMS unit
- 100041-3: Aminoglycoside [Susceptibility]
- 100042-1: Atovaquone [Susceptibility]
- 100043-9: Azithromycine+Éthambutol
|
FHIR